Edoxaban Effects on Bleeding Following Punch Biopsy and Reversal by a 4-Factor Prothrombin Complex Concentrate

被引:198
|
作者
Zahir, Hamim [1 ]
Brown, Karen S. [1 ]
Vandell, Alexander G. [1 ]
Desai, Madhuri [1 ]
Maa, Jen-Fue [2 ]
Dishy, Victor [1 ]
Lomeli, Barbara [3 ]
Feussner, Annette [4 ]
Feng, Wenqin [1 ]
He, Ling [1 ]
Grosso, Michael A. [1 ]
Lanz, Hans J. [1 ]
Antman, Elliott M. [5 ]
机构
[1] Daiichi Sankyo Pharma Dev, Edison, NJ 08837 USA
[2] Daiichi Sankyo Inc, Parsippany, NJ USA
[3] Quintiles Inc, Overland, KS USA
[4] CSL Behring GmbH, Marburg, Germany
[5] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA
关键词
anticoagulants; hemodynamics; thrombin; pharmacology; FACTOR XA INHIBITOR; PHARMACOKINETICS; DABIGATRAN; WARFARIN; RIVAROXABAN; ANTIDOTE; SAFETY; RFVIIA;
D O I
10.1161/CIRCULATIONAHA.114.013445
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background-The oral factor Xa inhibitor edoxaban has demonstrated safety and efficacy in stroke prevention in patients with atrial fibrillation and in the treatment and secondary prevention of venous thromboembolism. This study investigated the reversal of edoxaban's effects on bleeding measures and biomarkers by using a 4-factor prothrombin complex concentrate (4F-PCC). Methods and Results-This was a phase 1 study conducted at a single site. This was a double-blind, randomized, placebocontrolled, 2-way crossover study to determine the reversal effect of descending doses of 4F-PCC on bleeding duration and bleeding volume following edoxaban treatment. A total of 110 subjects (17 in part 1, 93 in part 2) were treated. Intravenous administration of 4F-PCC 50, 25, or 10 IU/kg following administration of edoxaban (60 mg) dose-dependently reversed edoxaban's effects on bleeding duration and endogenous thrombin potential, with complete reversal at 50 IU/kg. Effects on prothrombin time were partially reversed at 50 IU/kg. A similar trend was seen for bleeding volume. Conclusions-The 4F-PCC dose-dependently reversed the effects of edoxaban (60 mg), with complete reversal of bleeding duration and endogenous thrombin potential and partial reversal of prothrombin time following 50 IU/kg. Edoxaban alone and in combination with 4F-PCC was safe and well tolerated in these healthy subjects. A dose of 50 IU/kg 4F-PCC may be suitable for reversing edoxaban anticoagulation.
引用
收藏
页码:82 / +
页数:24
相关论文
共 50 条
  • [11] Modelling the effects of 4-factor prothrombin complex concentrate for the management of factor Xa-associated bleeding
    Muir, Ineke
    Herzog, Eva
    Brechmann, Markus
    Ghobrial, Oliver
    Rezvani Sharif, Alireza
    Hoffman, Maureane
    PLOS ONE, 2024, 19 (09):
  • [12] FIXED-DOSE 4-FACTOR PROTHROMBIN COMPLEX CONCENTRATE FOR WARFARIN REVERSAL
    Gomez, Leigh
    Langenhan, Emilie
    Blaha, Madeline
    CRITICAL CARE MEDICINE, 2023, 51 (01) : 379 - 379
  • [13] COMPARISON OF 4-FACTOR PROTHROMBIN COMPLEX CONCENTRATE DOSING STRATEGIES FOR WARFARIN REVERSAL
    Rivosecchi, Ryan
    Dibridge, Julie
    CRITICAL CARE MEDICINE, 2021, 49 (01) : 417 - 417
  • [14] IN VIVO REVERSAL OF THE ANTICOAGULANT EFFECT OF RIVAROXABAN WITH 4-FACTOR PROTHROMBIN COMPLEX CONCENTRATE
    Cheung, Whitney
    Barco, Stefano
    Coppens, Michiel
    Hutten, Barbara
    Meijers, Joost
    Middeldorp, Saskia
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 63 (12) : A334 - A334
  • [15] Protocolized warfarin reversal with 4-factor prothrombin complex concentrate versus 3-factor prothrombin complex concentrate with recombinant factor VIIa
    Barton, Cassie A.
    Hom, Marissa
    Johnson, Nathan B.
    Case, Jon
    Ran, Ran
    Schreiber, Martin
    AMERICAN JOURNAL OF SURGERY, 2018, 215 (05): : 775 - 779
  • [16] Reversal of Warfarin-Associated Major Hemorrhage: Activated Prothrombin Complex Concentrate versus 4-Factor Prothrombin Complex Concentrate
    Peksa, Gary D.
    Mokszycki, Robert K.
    Rech, Megan A.
    Maynard, Brian
    Panos, Nicholas G.
    Sweis, Rolla T.
    DeMott, Joshua M.
    THROMBOSIS AND HAEMOSTASIS, 2020, 120 (02) : 207 - 215
  • [17] Emergent Warfarin Reversal With Fixed-Dose 4-Factor Prothrombin Complex Concentrate
    Jansma, Brianna
    Montgomery, Josephine
    Dietrich, Scott
    Mixon, Mark A.
    Peksa, Gary D.
    Faine, Brett
    ANNALS OF PHARMACOTHERAPY, 2020, 54 (11) : 1090 - 1095
  • [18] Discussion of "Protocolized warfarin reversal with 4-factor prothrombin complex concentrate versus 3-factor prothrombin complex concentrate with recombinant factor VIIa"
    Van Dusen, Rachel
    AMERICAN JOURNAL OF SURGERY, 2018, 215 (05): : 780 - 781
  • [19] Evaluation of fixed dose 4-factor prothrombin complex concentrate for emergent warfarin reversal
    Klein, Lauren
    Peters, Jessica
    Miner, James
    Gorlin, Jed
    AMERICAN JOURNAL OF EMERGENCY MEDICINE, 2015, 33 (09): : 1213 - 1218
  • [20] CHARACTERIZING THE USE OF 4-FACTOR PROTHROMBIN COMPLEX CONCENTRATE
    Pajoumand, Mehrnaz
    Chaney, Whitney
    Mueller, Scott
    Shafeeq, Hira
    Daley, Mitchell
    Stump, Brian
    Hines, Michelle
    Rech, Megan
    Stein, Deborah
    CRITICAL CARE MEDICINE, 2018, 46 (01) : 266 - 266